Trials / Completed
CompletedNCT02055066
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This a first-in-human study of an antibody blocking the function of the oncogene c-met in patients with cancer.
Detailed description
This Phase 1b trial will characterize the safety profile of ARGX 111 and will thus provide the first elements towards establishing an accurate risk-benefit assessment for ARGX 111 in cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARGX-111 |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-02-04
- Last updated
- 2017-04-21
Locations
2 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02055066. Inclusion in this directory is not an endorsement.